NASDAQ:REGN - Regeneron Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
Get Started
$315.61 +0.31 (+0.10 %)
(As of 06/18/2018 04:00 PM ET)
Previous Close$315.30
Today's Range$309.71 - $316.26
52-Week Range$281.89 - $543.55
Volume614,500 shs
Average Volume921,351 shs
Market Capitalization$33.96 billion
P/E Ratio23.53
Dividend YieldN/A
Beta1.4

About Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals logoRegeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat adult patients with moderate-to-severe atopic dermatitis; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and Kevzara solution for subcutaneous injection to treat rheumatoid arthritis in adults. In addition, the company offers ARCALYST injection for cryopyrin-associated periodic syndromes; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. Further, it develops EYLEA, a trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma; and Dupixent, Praluent, Kevzara, Suptavumab, Cemiplimab, Fasinumab, Evinacumab, Nesvacumab/aflibercept, Trevogrumab, REGN1908-1909, REGN1979, REGN3470-3471-3479, REGN2477, REGN3500, REGN3767, and REGN3918, which are antibody-based clinical programs under various stages of development. The company has collaboration and license agreements with Sanofi, Bayer, Mitsubishi Tanabe Pharma, Teva, Intellia Therapeutics, Adicet Bio, Decibel Therapeutics, Astellas, Alnylam Pharmaceuticals, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

Receive REGN News and Ratings via Email

Sign-up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:REGN
CUSIP75886F10
Webwww.regeneron.com
Phone914-847-7000

Debt

Debt-to-Equity Ratio0.11
Current Ratio3.59
Quick Ratio2.94

Price-To-Earnings

Trailing P/E Ratio23.53
Forward P/E Ratio18.35
P/E Growth1.13

Sales & Book Value

Annual Sales$5.87 billion
Price / Sales5.79
Cash Flow$15.8758 per share
Price / Cash19.88
Book Value$57.09 per share
Price / Book5.53

Profitability

EPS (Most Recent Fiscal Year)$13.41
Net Income$1.20 billion
Net Margins23.54%
Return on Equity29.92%
Return on Assets20.79%

Miscellaneous

Employees6,200
Outstanding Shares107,700,000

Regeneron Pharmaceuticals (NASDAQ:REGN) Frequently Asked Questions

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced its quarterly earnings results on Thursday, May, 3rd. The biopharmaceutical company reported $4.67 EPS for the quarter, missing the consensus estimate of $5.08 by $0.41. The biopharmaceutical company earned $1.51 billion during the quarter, compared to analysts' expectations of $1.50 billion. Regeneron Pharmaceuticals had a return on equity of 29.92% and a net margin of 23.54%. The firm's revenue for the quarter was up 14.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.92 EPS. View Regeneron Pharmaceuticals' Earnings History.

When is Regeneron Pharmaceuticals' next earnings date?

Regeneron Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Regeneron Pharmaceuticals.

What price target have analysts set for REGN?

25 brokers have issued 1 year target prices for Regeneron Pharmaceuticals' stock. Their predictions range from $290.00 to $593.00. On average, they expect Regeneron Pharmaceuticals' stock price to reach $428.8333 in the next year. View Analyst Ratings for Regeneron Pharmaceuticals.

What are Wall Street analysts saying about Regeneron Pharmaceuticals stock?

Here are some recent quotes from research analysts about Regeneron Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Regeneron’s first-quarter results were mixed with earnings beating expectations while sales missed on the same. Nevertheless, we are encouraged by the pipeline progress. The potential label expansion of Eylea in patients with wet age-related macular degeneration will further boost sales.  A positive outcome will boost investor sentiment as well as the company had earlier suffered setback when it decided not to advance the nesvacumab and Eylea combination study to phase III development after two phase II studies evaluating the combination therapy failed to show additional benefit over Eylea monotherapy in patients with diabetic macular edema or wet age-related macular degeneration. Any setbacks will hurt the stock as the company is heavily dependent on Eylea. Meanwhile, Dupixent uptake in the United States for moderate-to-severe atopic dermatitis was encouraging. Shares have underperofrmed the industry in the last six months." (5/9/2018)
  • 2. Canaccord Genuity analysts commented, "We are encouraged by better US Dupixent growth, but recognize that the pediatric atopic dermatitis market will be the core growth driver, with approval expected around 2021. Also, while we understand that REGN and investors are focusing more on Dupixent’s growth than EYLEA’s, the lack of EYLEA guidance going forward is concerning. REGN cannot give guidance on Dupixent since Sanofi books the revenues, and EYLEA is still expected to be the core revenue driver for REGN." (2/7/2018)

Who are some of Regeneron Pharmaceuticals' key competitors?

Who are Regeneron Pharmaceuticals' key executives?

Regeneron Pharmaceuticals' management team includes the folowing people:
  • Dr. Leonard S. Schleifer, Co-Founder, Pres, CEO & Exec. Director (Age 65)
  • Dr. George D. Yancopoulos, Pres, Chief Scientific Officer & Director (Age 58)
  • Mr. Robert E. Landry Jr., Sr. VP of Fin. & CFO (Age 54)
  • Dr. Neil Stahl, Exec. VP of R&D (Age 61)
  • Mr. Daniel P. Van Plew, Exec. VP and Gen. Mang. of Industrial Operations & Product Supply (Age 45)

Has Regeneron Pharmaceuticals been receiving favorable news coverage?

Press coverage about REGN stock has been trending somewhat positive on Monday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Regeneron Pharmaceuticals earned a news sentiment score of 0.10 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 46.34 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include SANOFI (95.60%), BlackRock Inc. (5.57%), Loomis Sayles & Co. L P (2.62%), Polen Capital Management LLC (1.32%), Sustainable Growth Advisers LP (0.97%) and American Century Companies Inc. (0.89%). Company insiders that own Regeneron Pharmaceuticals stock include Arthur F Ryan, Charles A Baker, George L Sing, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry, Robert J Terifay and Sanofi. View Institutional Ownership Trends for Regeneron Pharmaceuticals.

Which institutional investors are selling Regeneron Pharmaceuticals stock?

REGN stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Millennium Management LLC, Sei Investments Co., Franklin Resources Inc., Senzar Asset Management LLC, Prudential Financial Inc., MUFG Securities EMEA plc and Swiss National Bank. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Charles A Baker, George L Sing, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry and Sanofi. View Insider Buying and Selling for Regeneron Pharmaceuticals.

Which institutional investors are buying Regeneron Pharmaceuticals stock?

REGN stock was purchased by a variety of institutional investors in the last quarter, including Loomis Sayles & Co. L P, Old Mutual Global Investors UK Ltd., Rockefeller Capital Management L.P., Summit Trail Advisors LLC, Sustainable Growth Advisers LP, American Century Companies Inc., BB Biotech AG and Natixis Advisors L.P.. View Insider Buying and Selling for Regeneron Pharmaceuticals.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $315.61.

How big of a company is Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals has a market capitalization of $33.96 billion and generates $5.87 billion in revenue each year. The biopharmaceutical company earns $1.20 billion in net income (profit) each year or $13.41 on an earnings per share basis. Regeneron Pharmaceuticals employs 6,200 workers across the globe.

How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]


MarketBeat Community Rating for Regeneron Pharmaceuticals (REGN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  1,052 (Vote Outperform)
Underperform Votes:  863 (Vote Underperform)
Total Votes:  1,915
MarketBeat's community ratings are surveys of what our community members think about Regeneron Pharmaceuticals and other stocks. Vote "Outperform" if you believe REGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/18/2018 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.